Wegovy price cut for cash

Novo Nordisk started selling Wegovy to cash-paying patients for a flat $499 a month through NovoCare Pharmacy, a direct-to-patient channel the company launched on March 5, 2025. (prnewswire.com) The offer covered every FDA-approved Wegovy pen strength then on the market — 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg — and Novo Nordisk said shipments would go straight to patients’ homes. The company said the program was aimed at people without insurance coverage for the drug. (prnewswire.com) Less than three weeks later, on March 24, 2025, Novo Nordisk widened the same $499 price to eligible cash-paying patients filling Wegovy at retail pharmacies, not just through NovoCare Pharmacy. The company said patients could redeem the savings offer at the pharmacy of their choice. (novonordisk.mediaroom.com) The timing followed a major supply shift. On February 21, 2025, the U.S. Food and Drug Administration said the shortage of injectable semaglutide products, including Wegovy and Ozempic, was resolved and that supply now met or exceeded current and projected U.S. demand. (fda.gov) That mattered because Wegovy is Novo Nordisk’s branded semaglutide shot for chronic weight management, and the shortage had pushed many patients toward compounding pharmacies and other workarounds. Novo Nordisk tied the NovoCare launch to “fake or illegitimate compounded semaglutide” concerns, while the FDA has separately warned that compounded GLP-1 drugs are not FDA-approved and has logged hundreds of adverse-event reports tied to compounded semaglutide. (prnewswire.com) (fda.gov) Novo Nordisk was also responding to Eli Lilly’s cash-pay playbook. Lilly launched lower-priced Zepbound vials through LillyDirect in 2024, then expanded discounts in March 2025 and again in June 2025, bringing all approved vial doses to $499 a month or less for self-pay patients. (cnbc.com) (prnewswire.com 1) (prnewswire.com 2) The price war did not stop with injections. Eli Lilly said on April 9, 2026, that its newly approved oral GLP-1 pill Foundayo became available through LillyDirect after FDA approval on April 1, 2026, adding a daily pill to a market that had been dominated by weekly shots. (prnewswire.com) Novo Nordisk’s own cash-pay terms have already moved again. NovoCare’s current pharmacy page says new patients pay $199 for each of the first two monthly fills of Wegovy 0.25 mg and 0.5 mg through June 30, 2026, then $349 a month for Wegovy 0.25 mg through 2.4 mg, with separate pricing for the newer Wegovy HD 7.2 mg. (novocare.com) The result is a market where uninsured patients are no longer looking at one list price and one pharmacy counter. They are choosing among manufacturer-run channels, retail pharmacy discounts, pens versus vials, and now pills versus injections. (novocare.com) (zepbound.lilly.com) (prnewswire.com)